CSF Biomarker May Support Lewy Body Diagnosis - Takeaways - MDSpire
Advertisement
CSF Biomarker May Support Lewy Body Diagnosis
A multicohort analysis suggests cerebrospinal fluid DOPA decarboxylase may help distinguish dementia with Lewy bodies and Parkinson’s disease from Alzheimer’s disease and controls
Elevated cerebrospinal fluid levels of DOPA decarboxylase may aid in diagnosing Lewy body disorders like Parkinson's disease and dementia with Lewy bodies.
2
CSF DDC concentrations were significantly higher in Lewy body disorders compared to cognitively healthy controls and Alzheimer’s disease.
3
Models using CSF DDC, age, and sex showed strong diagnostic performance for distinguishing Lewy body disorders from other conditions.
4
Higher CSF DDC levels correlated with specific clinical features in dementia with Lewy bodies, such as parkinsonian symptoms and visual hallucinations.
5
The study suggests CSF DDC may reflect dopaminergic neuronal dysfunction, but further research is needed to confirm its diagnostic utility.
